TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:37
Allakos Inc. ( ALLK ) https://www.allakos.com
1.26USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-54.18%
ALLK
SPY
32.66%
-87.51%
ALLK
SPY
108.59%
-98.71%
ALLK
SPY
302.52%
ALLK
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
106.83
53.12
0.20
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.60
9.93
1.47
-187.17
0.00
-0.39
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-679.33
-9.97
-319.43
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.0736
-104.28
-50.12
1.02
Other Earnings and Cash Flow Stats:
Allakos Inc. ( ALLK ) Net Income TTM ($MM) is -178.75
Allakos Inc. ( ALLK ) Operating Income TTM ($MM) is -186.44
Allakos Inc. ( ALLK ) Owners' Earnings Annual ($MM) is 0.00
Allakos Inc. ( ALLK ) Current Price to Owners' Earnings ratio is 0.00
Allakos Inc. ( ALLK ) EBITDA TTM ($MM) is -181.95
Allakos Inc. ( ALLK ) EBITDA Margin is -319.43%
Capital Allocation:
Allakos Inc. ( ALLK ) has paid 0.00 dividends per share and bought back -1.909 million shares in the past 12 months
Allakos Inc. ( ALLK ) has reduced its debt by 2.766 million USD in the last 12 months
Capital Structure:
Allakos Inc. ( ALLK ) Interest-bearing Debt ($MM) as of last quarter is 39
Allakos Inc. ( ALLK ) Annual Working Capital Investments ($MM) are 41
Allakos Inc. ( ALLK ) Book Value ($MM) as of last quarter is 72
Allakos Inc. ( ALLK ) Debt/Capital as of last quarter is 53%
Other Balance Sheet Stats:
Allakos Inc. ( ALLK ) has 10 million in cash on hand as of last quarter
Allakos Inc. ( ALLK ) has 15 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Allakos Inc. ( ALLK ) has 89 common shares outstanding as of last quarter
Allakos Inc. ( ALLK ) has 0 million USD of preferred stock value
Academic Scores:
Allakos Inc. ( ALLK ) Altman Z-Score is -15.27 as of last quarter
Allakos Inc. ( ALLK ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Allakos Inc. ( ALLK ) largest shareholder is owning shares at 0.00 ($MM) value
Radford Harlan Baird(an insider) Sold 87064 shares of Allakos Inc. ( ALLK ) for the amount of $87934.64 on 2024-06-28
2.13% of Allakos Inc. ( ALLK ) is held by insiders, and 81.58% is held by institutions
Allakos Inc. ( ALLK ) went public on 2018-07-19
Other Allakos Inc. ( ALLK ) financial metrics:
FCF:-105.54
Unlevered Free Cash Flow:0.00
EPS:-0.83
Operating Margin:-679.33
Gross Profit Margin:-9.97
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-101.02
Beta:1.02
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Allakos Inc. ( ALLK ) :
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.